Clinical trials: Benign Prostate Hyperplasia
Prostatic Hyperplasia
Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia
Open-label, 6 month-treatment with the IP in all subjects. - Sample size: A total of 90 subjects will be enrolled so that among them at least 57 will complete the 6-month treatment period and evaluable for analysis.
- Trial name
- FDC114785 (NCT01673490)
- Testing
- Dutasteride/Tamsulosin
- Where
- Vietnam
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study
Primary: To assess improvement in ejaculation from baseline to the end of treatment (Week 12 or premature withdrawal) with Alfuzosin 10mg OD, using MSHQ score.
- Trial name
- NCT00427882
- Testing
- ALFUZOSIN
- Where
- South Korea
- Volunteers
- 125 people
- Sponsor
- Handok Inc.
Benign Prostatic Hyperplasia
Evaluating the Safety and Efficacy of the "HIFU" High-intensity Focused Ultrasound Treatment of Benign Prostatic Hyperplasia;
Prostate adenoma, also known as benign prostatic hypertrophy or hyperplasia (BPH), involves an increase in the size of the prostate, forming a benign tumor.
- Trial name
- BPH EFFICACY (NCT06601179)
- Testing
- HIFU
- Where
- 9 sites in France
- Volunteers
- 100 people
- Sponsor
- EDAP TMS S.A.
Benign Prostatic Hyperplasia (BPH)
To Establish the Safety and Effectiveness of the ALPFA GRAIL PFA System for Treating Symptomatic Benign Prostate Hyperplasia (BPH) Also Known as an Enlarged Prostate.
The main goal of this study is to evaluate the ALPFA GRAIL™ Pulsed Field Ablation (PFA) System for treatment of enlarged prostate (BPH) symptoms.
- Trial name
- REBOUND (NCT07592299)
- Testing
- Treatment Device: The ALPFA Medical (ALPFA) GRAIL™ Pulsed Field Ablation (PFA) System
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- ALPFA Medical
Benign Prostatic Hyperplasia
OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
APEX is a prospective multi-site registry of real-world experience with the Optilume™ BPH Catheter System for treatment of men experiencing symptomatic BPH.
- Trial name
- APEX (NCT06560476)
- Testing
- Data collection
- Where
- 8 sites in United States
- Volunteers
- 500 people
- Sponsor
- Urotronic Inc.
BPH (Benign Prostatic Hyperplasia)
The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH
The goal of this clinical trial is to learn if Qianweitai (QWT, silodosin capsule) works to treat BPH/LUTS in male adults. It will also learn the safety about QWT. The main questions it aims to answer are: 1.
- Trial name
- NCT07134907
- Testing
- Silodosin, Tamsolusin
- Where
- 6 sites in China
- Volunteers
- 110 people
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
Benign Prostatic Hyperplasia
Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III
A dual-arm prospective, interventional clinical trial to evaluate the safety and performance of obtaining hemostasis with catheters along with the use or absence of a hemostatic agent following treatment with the AQUABEAM System.
- Trial name
- AHAIII (NCT04308070)
- Testing
- AQUABEAM System followed by catheter without hemostatic agent, AQUABEAM System followed by catheter with hemostatic agent
- Where
- India
- Volunteers
- 26 people
- Sponsor
- PROCEPT BioRobotics
Benign Prostatic Hyperplasia, Enlarged Prostate
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
The purpose of this study is to investigate the efficacy and safety of once daily tadalafil when taken with finasteride as a treatment for men with signs and symptoms of Benign Prostatic Hyperplasia and demonstrable prostate…
- Trial name
- NCT01139762
- Testing
- Tadalafil, Finasteride
- Where
- 65 sites in United States, Argentina and 11 more
- Volunteers
- 696 people
- Sponsor
- Eli Lilly and Company
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH
Clinical Trial to Compare the Efficacy and Safety of Solifenacin/Tamsulosin Combination Therapy with Tamsulosin Monotherapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
- Trial name
- NCT02972268
- Testing
- Tamsulosin 0.2mg + Solifenacin 5mg
- Where
- South Korea
- Volunteers
- 780 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Benign Prostatic Hyperplasia, Localized Prostate Cancer
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are…
- Trial name
- NCT06051942
- Testing
- Robotic Waterjet Treatment
- Where
- 6 sites in United States, Hong Kong and 2 more
- Volunteers
- 125 people
- Sponsor
- PROCEPT BioRobotics
Prostatic Hyperplasia
The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)
Study to assess efficacy, tolerability and safety parameters of a three month ALNA®OCAS® -treatment with special respect to nocturia
- Trial name
- NCT02245542
- Testing
- ALNA®OCAS®
- Volunteers
- 5,775 people
- Sponsor
- Boehringer Ingelheim
Benign Prostate Hyperplasia, Erectile Dysfunction
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
The purpose of this study is to see whether tadalafil can reduce the signs and symptoms in men with Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia-Lower Urinary Tract Symptoms (BPH-LUTS) and improve their quality of…
- Trial name
- NCT01937871
- Testing
- 5 mg Tadalafil, 0.2 mg Tamsulosin
- Where
- 14 sites in China
- Volunteers
- 909 people
- Sponsor
- Eli Lilly and Company
BPH (Benign Prostatic Hyperplasia)
Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry
The purpose of this registry is to collect information on how the Zenflow Spring System works in everyday medical practice. The registry will track how the Spring System performs during the implant procedure, and at follow-up…
- Trial name
- NCT07538622
- Testing
- Zenflow Spring System
- Where
- 8 sites in United States
- Volunteers
- 300 people
- Sponsor
- Zenflow, Inc.
Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Safety and Efficacy of OCL 503 in Prostate Artery Embolization
This is a prospective, pilot, open-label, uncontrolled, non-randomized safety and effectiveness study of OCL 503 in men with BPH.
- Trial name
- NCT02509975
- Testing
- Prostate artery embolization.
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- IMBiotechnologies Ltd.
Benign Prostatic Hyperplasia (BPH), Overactive Bladder
A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.
To evaluate the influence of BR9006-1 and BR9006-2 on pharmacokinetics, safety, and tolerability when administered separately or co-administered to healthy male volunteers.
- Trial name
- NCT04485585
- Testing
- BR9006-1, BR9006-2
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Benign Prostatic Hyperplasia
Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)
This is a phase 3, randomized, double-blind, placebo-controlled, parallel-design, multinational study to evaluate the efficacy and safety of tadalafil once-a-day dosing for 12 weeks in Asian men with signs and symptoms of benign…
- Trial name
- NCT01460342
- Testing
- Tadalafil
- Where
- 17 sites in Japan, South Korea
- Volunteers
- 610 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily
The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your…
- Trial name
- NCT00827242
- Testing
- tadalafil
- Where
- 27 sites in United States, Argentina and 3 more
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.
- Trial name
- NCT00224133
- Testing
- Silodosin
- Where
- 79 sites in United States
- Volunteers
- 661 people
- Sponsor
- Watson Pharmaceuticals
Benign Prostatic Hyperplasia
Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode
The purpose of this observational study is to evaluate the outcomes of using the PlasmaButton electrode in the treatment on Benign Prostatic Hyperplasia (BPH) while on anticoagulation medication.
- Trial name
- NCT02019030
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Olympus Corporation of the Americas
Benign Prostatic Hyperplasia (BPH)
To Evaluate the Feasibility, Preliminary Safety and Performance of Rezūm System in BPH Treatment in China
A real world study to evaluate the feasibility, preliminary safety and performance of Rezūm system in BPH treatment in China Rezūm RWS study
- Trial name
- NCT04823221
- Testing
- Rezūm System
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Boston Scientific Corporation